T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

doi:10.1016/j.antiviral.2016.11.006

科研成果详情

题名	T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
作者	Liu, William J.1,2,3; Zhao, Min 4,5; Liu, Kefang 1,2; Xu, Kun 4,5,6; Wong, Gary 3,4; Tan, Wenjie1,2; Gao, George F.1,3,4,5,6
发表期刊	ANTIVIRAL RESEARCH 影响因子和分区
语种	英语
原始文献类型	Review
关键词	SARS-CoV MERS-CoV Vaccine T -cell Epitope Cross-reactivity
其他关键词	ACUTE-RESPIRATORY-SYNDROME ; RECEPTOR-BINDING DOMAIN ; CORONAVIRUS NUCLEOCAPSID PROTEIN ; CENTRAL-NERVOUS-SYSTEM ; SPIKE PROTEIN ; I INTERFERON ; S-PROTEIN ; NEUTRALIZING ANTIBODY ; LYMPHOCYTE EPITOPES ; MEMBRANE-PROTEIN
摘要	Over 12 years have elapsed since severe acute respiratory syndrome (SARS) triggered the first global alert for coronavirus infections. Virus transmission in humans was quickly halted by public health measures and human infections of SARS coronavirus (SARS-CoV) have not been observed since. However, other coronaviruses still pose a continuous threat to human health, as exemplified by the recent emergence of Middle East respiratory syndrome (MERS) in humans. The work on SARS-CoV widens our knowledge on the epidemiology, pathophysiology and immunology of coronaviruses and may shed light on MERS coronavirus (MERS-CoV). It has been confirmed that T-cell immunity plays an important role in recovery from SARS-CoV infection. Herein, we summarize T-cell immunological studies of SARS-CoV and discuss the potential cross-reactivity of the SARS-CoV-specific immunity against MERS-CoV, which may provide useful recommendations for the development of broad-spectrum vaccines against coronavirus infections. (C) 2016 Elsevier B.V. All rights reserved.
资助项目	China Mega-Project on Infectious Disease Prevention [2016ZX10004222-003, 2014ZX10004001-006, 2013ZX10004608-002]; National 973 Project of the China Ministry of Science and Technology [2015CB910500, 2011CB504700]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81401312, 31390432, 81373141]; National Natural Science Foundation of China Innovative Research Group [81321063]
出版者	ELSEVIER SCIENCE BV
出版地	AMSTERDAM
ISSN	0166-3542
EISSN	1872-9096
卷号	137 页码:82-92
DOI	10.1016/j.antiviral.2016.11.006
WOS类目	Pharmacology & Pharmacy ; Virology
WOS研究方向	Pharmacology & Pharmacy ; Virology
WOS记录号	WOS:000393005300010
收录类别	SCIE ; PUBMED ; SCOPUS
发表日期	2017-01
URL	查看原文
Pubmed记录号	27840203
PMC记录号	PMC7113894
Scopus记录号	2-s2.0-85005943436
ESI高被引论文	2020-09 ; 2020-11 ; 2021-01 ; 2021-03 ; 2021-05 ; 2021-07 ; 2021-09 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-05 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05
引用统计	被引频次：216[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/19788
专题	检验医学院（生命科学学院、生物学实验教学中心）
通讯作者	Liu, William J.; Gao, George F.
作者单位	1.China CDC, Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing 100052, Peoples R China; 2.Wenzhou Med Univ, Coll Lab Med & Life Sci, Wenzhou 325035, Peoples R China; 3.Shenzhen Third Peoples Hosp, Shenzhen Key Lab Pathogen & Immun, Shenzhen 518112, Peoples R China; 4.Chinese Acad Sci, Inst Microbiol, CAS Key Laboratozy Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China; 5.Univ Chinese Acad Sci, Beijing 100049, Peoples R China; 6.Chinese Acad Sci, Being Inst Life Sci, RNIH, Beijing 100101, Peoples R China
第一作者单位	检验医学院（生命科学学院、生物学实验教学中心）
通讯作者单位	检验医学院（生命科学学院、生物学实验教学中心）
推荐引用方式 GB/T 7714	Liu, William J.,Zhao, Min,Liu, Kefang,et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV[J]. ANTIVIRAL RESEARCH,2017,137:82-92.
APA	Liu, William J.., Zhao, Min., Liu, Kefang., Xu, Kun., Wong, Gary., ... & Gao, George F.. (2017). T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. ANTIVIRAL RESEARCH, 137, 82-92.
MLA	Liu, William J.,et al."T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV".ANTIVIRAL RESEARCH 137(2017):82-92.